Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes a rotatably mounted first gear wheel having ratchet teeth and a display coupled to the first gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the first gear wheel. The dose counter further includes an actuator mechanism having a first ratchet drive pawl for engaging the ratchet teeth of the first gear wheel in response to the dispensation of a medicament dose, and a second ratchet drive pawl for engaging the ratchet teeth of a gear wheel coupled to the display. In use, a first ratchet tooth of the first gear wheel is rotatably driven by the first pawl and then a second ratchet tooth of the gear wheel coupled to the display is rotatably driven by the second pawl.

Abstract: A dose counter for counting does of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes a rotatably mounted gear wheel having a circular arrangement of ratchet teeth defining a root circle and a display coupled to the gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the gear wheel. The dose counter further includes an actuator mechanism having a driver for rotatably driving the gear wheel in response to the dispensation of a medicament dose, the driver being arranged to engage the ratchet teeth of the gear wheel. The actuator mechanism includes an actuator shaft mounted for linear movement in response to the dispensing of a dose of medicament. In use, the travel of the driver along the root circle of the gear wheel exceeds the corresponding linear movement of the actuator shaft.

Abstract: The present disclosure encompasses crystalline forms of Afatininb di-maleate and methods of their use.

Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes: a rotatably mounted gear wheel having a circular arrangement of ratchet teeth; a display coupled to the gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the gear wheel; and an actuator mechanism having a driver for rotatably driving the gear wheel in response to the dispensation of a medicament dose, the driver being arranged to engage the ratchet teeth of the gear wheel. The actuator mechanism includes a pivotally mounted lever having an input portion. The lever is arranged to amplify a linear stroke at the input portion such that a linear stroke of the driver exceeds the linear input stroke. By amplifying the stroke, the risk of undercounting due to insufficient stroke length may be reduced.

Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.

Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes a rotatably mounted first gear wheel having ratchet teeth and a display coupled to the first gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the first gear wheel. The dose counter further includes an actuator mechanism having a first ratchet drive pawl for engaging the ratchet teeth of the first gear wheel in response to the dispensation of a medicament dose, and a second ratchet drive pawl for engaging the ratchet teeth of a gear wheel coupled to the display. In use, a first ratchet tooth of the first gear wheel is rotatably driven by the first pawl and then a second ratchet tooth of the gear wheel coupled to the display is rotatably driven by the second pawl.

Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes: a rotatably mounted gear wheel having a circular arrangement of ratchet teeth; a display coupled to the gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the gear wheel; and an actuator mechanism having a driver for rotatably driving the gear wheel in response to the dispensation of a medicament dose, the driver being arranged to engage the ratchet teeth of the gear wheel. The actuator mechanism includes a pivotally mounted lever having an input portion. The lever is arranged to amplify a linear stroke at the input portion such that a linear stroke of the driver exceeds the linear input stroke. By amplifying the stroke, the risk of undercounting due to insufficient stroke length may be reduced.

Abstract: This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.

Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or as pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release said oral dosage form.

Abstract: This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.

Abstract: This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydrochloride salt, a process for the preparation of this polymorphic form, pharmaceutical compositions comprising polymorphic Form II, and methods of uses of this polymorphic form.

Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 90 mg of pridopidine is administered to the patient per day.

Abstract: This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydrochloride salt, a process for the preparation of this polymorphic form, pharmaceutical compositions comprising polymorphic Form II, and methods of uses of this polymorphic form.

Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes: a rotatably mounted gear wheel having a circular arrangement of ratchet teeth; a display coupled to the gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the gear wheel; and an actuator mechanism having a driver for rotatably driving the gear wheel in response to the dispensation of a medicament dose, the driver being arranged to engage the ratchet teeth of the gear wheel. The actuator mechanism includes a pivotally mounted lever having an input portion. The lever is arranged to amplify a linear stroke at the input portion such that a linear stroke of the driver exceeds the linear input stroke. By amplifying the stroke, the risk of undercounting due to insufficient stroke length may be reduced.

Abstract: A dose counter for counting doses of medicament dispensed by or remaining in a metered-dose inhaler. The dose counter includes: a rotatably mounted gear wheel having a circular arrangement of ratchet teeth; a display coupled to the gear wheel, the display having a visible array of dose counting indicia indexable in response to rotary motion of the gear wheel; and an actuator mechanism having a driver for rotatably driving the gear wheel in response to the dispensation of a medicament dose, the driver being arranged to engage the ratchet teeth of the gear wheel. The actuator mechanism includes a pivotally mounted lever having an input portion. The lever is arranged to amplify a linear stroke at the input portion such that a linear stroke of the driver exceeds the linear input stroke. By amplifying the stroke, the risk of undercounting due to insufficient stroke length may be reduced.

Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.

Abstract: The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.

Abstract: This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.

Abstract: The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.